๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC ยท Real-Time Price ยท USD
0.1680
-0.0160 (-8.70%)
Nov 20, 2026, 4:00 PM EST - Market closed

IGC Pharma Earnings Call Transcripts

Fiscal Year 2026

  • Status update

    Phase II CALMA trial for a cannabinoid-based Alzheimer's therapy is 70% enrolled and on track for completion by mid-year, with top-line data expected by late summer. The MINT-AD AI platform for Alzheimer's risk assessment will enter beta testing soon, and regulatory trends favor expansion of cannabinoid-based treatments.

Fiscal Year 2025

  • IGC 81's phase two trial for Alzheimer's agitation surpassed 50% enrollment, with accelerated recruitment and expansion to 35 sites in the U.S. and Canada. Strategic divestment improved financials, and the AI-based MINT-AD platform advanced to the semifinals for a $1M research prize.

  • IGC81 demonstrated rapid and significant efficacy in phase II trials for Alzheimer's agitation, while the AI-based MINT-AD platform advanced early detection capabilities. Efficient capital management and pipeline expansion into GLP-1 agonists position the company for growth.